New USA headquarters and new certifications
New York, May 13, 2022: We are pleased to announce the move of our new USA Headquarters to the beating heart of the Big Apple, with offices located in a prestigious location in New York City and precisely at 509 Madison Avenue in the center of Manatthan.
This big step is a consequence of the strong growth of activities in North America, attested by the new FDA approvals also for the EchoSK and EchoS Gyn software applications, two optional modules of our device that allow the use of R.E.M.S. also in musculoskeletal and gynecological applications, and by another important overseas registration recently obtained, the Medical Device License issued by the Canadian health authority “Health Canada”, thanks to which the marketing of our devices on Canadian has been authorized and already started a few months ago by our local partner.
Echolight therefore evolves and grows continuously, positioning where “things happen”.
Contact us here for activities in North America:
509 Madison Ave RM 1510
New York, New York 10022, USA
+1-833-263-7367
+1 425 658 060
About Echolight
Echolight Medical has developed the first clinically available method for the direct non-ionizing measurement of lumbar and femoral bone mineral density (BMD).
The device, EchoS, utilizes proprietary R.E.M.S. (Radiofrequency Echographic Multi Spectrometry) technology to scan the lumbar vertebrae and proximal femur. The EchoS rapidly generates a medical report that includes BMD, T-score and Z-score. In addition, the system automatically assesses the quality of bone micro architecture, independent of BMD, and provides a five-year probability of a major osteoporosis fracture.
EchoS offers significantly increased levels of accuracy, sensitivity to bone mass changes and diagnostic reproducibility over DXA systems. This, coupled with the absence of ionizing radiation, allows for osteoporosis diagnosis at the point of care more broadly and at an earlier stage. It also enables more accurate monitoring post diagnosis. Learn more about the FDA-cleared EchoS at: www.echolightmedical.com.
REMS & Diabete
The Advantages of REMS Technology in Type 2 Diabetes Mellitus The study “Utility of REMS-Derived Fragility Score and Trabecular Bone Score in Evaluating Bone Health in Type 2 Diabetes Mellitus” recently published by Al Refaie and colleagues in Diagnostics Journal...
REMS Performance
The very recent study titled “Proposed practice parameters for the performance of radiofrequency Echographic multispectrometry (REMS) evaluations” and published on the Bone Joint Open by international key Opinion Leaders from USA and UK showed that REMS are becoming a...
Position Paper by ESCEO
“Radiofrequency echographic multi spectrometry (REMS) in the diagnosis and management of osteoporosis: state of the art.” ESCEO WORKING GROUPNicholas R Fuggle, Jean-Yves Reginster · Nasser Al-Daghri · Olivier Bruyere · Nansa Burlet · Claudia Campusano6 · Cyrus Cooper...